Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy
2025 ASCO Annual Meeting
Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer.
The ASCO Post Staff
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.
The ASCO Post Staff
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).
The ASCO Post Staff
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500).
The ASCO Post Staff
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with ER-positive HER2-negative advanced breast cancer. Vepdegestrant is the first PROTAC to be evaluated in a phase III trial (Abstract LBA1000).
